The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 16: 2112 - 2115

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.16.017

Drugs and Clinic Practice

Efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating advanced non-small cell lung cancer

  • Xianlan ZHANG ,
  • Yufei ZHU ,
  • Yunyun ZENG ,
  • Zhihao HUANG ,
  • Wenchang CEN ,
  • Shan. SU
Expand
  • *.Department of Oncology，Guangzhou Chest Hospital，Guangzhou 510095，China

Received date: 2023-04-27

  Online published: 2023-09-26

Fold

Abstract

Objective To investigate the efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating patients with advanced non-small cell lung cancer （NSCLC）. Methods We retrospectively reviewed and analyzed the medical records of 24 patients with advanced NSCLC treated with chemotherapy plus immunotherapy and recombinant human endostatin in Guangzhou Chest Hospital from June 2020 to December 2022. We focused on analyses of progression-free survival （PFS） and objective response rate （ORR） as well as disease control rate （DCR） and adverse events （AEs）. Results At 19.2 months′ median follow-up， the median PFS （mPFS） was 11 months （95%CI：8.722 ~ 13.278）. Among them， 11 patients received first-line treatment with an mPFS of 11 months （95%CI：9.782 ~ 12.218）. The 6-month and 12-month PFS rates were 82.4% and 52.9%， respectively. The first-line treatment elicited an ORR of 58.8%， and a DCR of 94.1%. Among the 17 cases， 2 came out with grade 3 - 4 AEs， taking up 11.8%， among which hematotoxicity was the most common， and 8 with grade 1 - 2 AEs， taking up 47.1%， among which hematotoxicity accounted for 17.6%， pruritus for 17.6% and hepatic toxicity for 5.9%. Conclusion Chemotherapy plus immunotherapy and endostatin promises good efficacy and safety in treating patients with advanced NSCLC.

Key words： lung cancer; non-small cell; chemotherapy; immunotherapy; recombinant human endostatin

Cite this article

Xianlan ZHANG , Yufei ZHU , Yunyun ZENG , Zhihao HUANG , Wenchang CEN , Shan. SU . Efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating advanced non-small cell lung cancer[J]. The Journal of Practical Medicine, 2023 , 39(16) : 2112 -2115 . DOI: 10.3969/j.issn.1006-5725.2023.16.017

References

1 RECK M， REMON J， HELLMANN M D. First-Line Immunotherapy for Non-Small-Cell Lung Cancer［J］. J Clin Oncol， 2022，40（6）：586-597.
2 PETITPREZ F， MEYLAN M， DE REYNIèS A， et al. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies［J］. Front Immunol， 2020，11：784.
3 JAIN R K. Normalization of tumor vasculature： an emerging concept in antiangiogenic therapy［J］. Science， 2005，307（5706）：58-62.
4 HU H， CHEN Y， TAN S， et al. The Research Progress of Antiangiogenic Therapy， Immune Therapy and Tumor Microenvironment［J］. Front Immunol， 2022，13：802846.
5 REN S， XIONG X， YOU H， et al. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer［J］. Front Immunol， 2021，12：689132.
6 LING Y， YANG Y， LU N， et al. Endostar， a novel recombinant human endostatin， exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells［J］. Biochem Biophys Res Commun， 2007，361（1）：79-84.
7 HU W， FANG J， NIE J， et al. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer［J］. Medicine （Baltimore）， 2016，95（28）：e4183.
8 MéNDEZ-VALDéS G， GóMEZ-HEVIA F， LILLO-MOYA J， et al. Endostatin and Cancer Therapy： A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies［J］. Biomedicines， 2023，11（3）：718.
9 ZHOU C， WANG Z， SUN Y， et al. Sugemalimab versus placebo， in combination with platinum-based chemotherapy， as first-line treatment of metastatic non-small-cell lung cancer （GEMSTONE-302）： interim and final analyses of a double-blind， randomised， phase 3 clinical trial［J］. Lancet Oncol， 2022，23（2）：220-233.
10 WANG Z， WU L， LI B， et al. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer： A Multicenter Randomized Phase III Trial （CHOICE-01） ［J］. J Clin Oncol， 2023，41（3）：651-663.
11 SONG Y， FU Y， XIE Q，et al. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors： A Promising Strategy for Cancer Treatment［J］. Front Immunol， 2020，11：1956.
12 RECK M， MOK TSK， NISHIO M， et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer （IMpower150）： key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised， open-label phase 3 trial［J］. Lancet Respir Med， 2019，7（5）：387-401.
13 CHU T， ZHONG R， ZHONG H， et al. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC［J］. J Thorac Oncol， 2021，16（4）：643-652.
14 武阳，陆翰杰，水会锋.既往免疫经治的晚期非小细胞肺癌患者接受安罗替尼联合PD-1单抗的疗效及安全性［J］. 实用医学杂志， 2023，39（5）：572-578.
15 LV W， PEI X， ZHAO W， et al. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer［J］. Transl Lung Cancer Res， 2022，11（2）：201-212.
16 WANG B， XU L， LI Q， et al. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC： a systematic review and meta-analysis including non-randomized studies［J］. BMC Cancer， 2020，20（1）：1021.
Options
Outlines

/

〈 〉